BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Triulzi T, Regondi V, De Cecco L, Cappelletti MR, Di Modica M, Paolini B, Lollini PL, Di Cosimo S, Sfondrini L, Generali D, Tagliabue E. Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit. Br J Cancer 2018;119:1487-94. [PMID: 30478407 DOI: 10.1038/s41416-018-0318-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Tolba MF, Elghazaly H, Bousoik E, Elmazar MMA, Tolaney SM. Novel combinatorial strategies for boosting the efficacy of immune checkpoint inhibitors in advanced breast cancers. Clin Transl Oncol 2021;23:1979-94. [PMID: 33871826 DOI: 10.1007/s12094-021-02613-w] [Reference Citation Analysis]
2 Janjigian YY, Kawazoe A, Yañez P, Li N, Lonardi S, Kolesnik O, Barajas O, Bai Y, Shen L, Tang Y, Wyrwicz LS, Xu J, Shitara K, Qin S, Van Cutsem E, Tabernero J, Li L, Shah S, Bhagia P, Chung HC. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature 2021;600:727-30. [PMID: 34912120 DOI: 10.1038/s41586-021-04161-3] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Hamilton EP, Kaklamani V, Falkson C, Vidal GA, Ward PJ, Patre M, Chui SY, Rotmensch J, Gupta K, Molinero L, Li Y, Emens LA. Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib Study. Clin Breast Cancer 2021:S1526-8209(21)00089-6. [PMID: 34154926 DOI: 10.1016/j.clbc.2021.04.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Maia A, Wiemann S. Cancer-Associated Fibroblasts: Implications for Cancer Therapy. Cancers (Basel) 2021;13:3526. [PMID: 34298736 DOI: 10.3390/cancers13143526] [Reference Citation Analysis]
5 Corogeanu D, Diebold SS. Direct and Indirect Engagement of Dendritic Cell Function by Antibodies Developed for Cancer Therapy. Clin Exp Immunol 2022:uxac026. [PMID: 35352109 DOI: 10.1093/cei/uxac026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Bugide S, Gupta R, Green MR, Wajapeyee N. EZH2 inhibits NK cell-mediated antitumor immunity by suppressing CXCL10 expression in an HDAC10-dependent manner. Proc Natl Acad Sci U S A 2021;118:e2102718118. [PMID: 34301901 DOI: 10.1073/pnas.2102718118] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Petroni G, Buqué A, Coussens LM, Galluzzi L. Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment. Nat Rev Drug Discov 2022. [PMID: 35292771 DOI: 10.1038/s41573-022-00415-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
8 Chun BM, Page DB, Mcarthur HL. Combination Immunotherapy Strategies in Breast Cancer. Curr Breast Cancer Rep 2019;11:228-40. [DOI: 10.1007/s12609-019-00333-3] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 Caparica R, Ma Y, De Angelis C, Richard F, Desmedt C, Awada A, Piccart M, Perez EA, Moreno-Aspitia A, Badve S, Thompson EA, de Azambuja E. Beta-2 Adrenergic Receptor Gene Expression in HER2-Positive Early-Stage Breast Cancer Patients: A Post-hoc Analysis of the NCCTG-N9831 (Alliance) Trial. Clin Breast Cancer 2021:S1526-8209(21)00351-7. [PMID: 34980541 DOI: 10.1016/j.clbc.2021.11.012] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Wingerter A, El Malki K, Sandhoff R, Seidmann L, Wagner DC, Lehmann N, Vewinger N, Frauenknecht KBM, Sommer CJ, Traub F, Kindler T, Russo A, Otto H, Lollert A, Staatz G, Roth L, Paret C, Faber J. Exploiting Gangliosides for the Therapy of Ewing's Sarcoma and H3K27M-Mutant Diffuse Midline Glioma. Cancers (Basel) 2021;13:520. [PMID: 33572900 DOI: 10.3390/cancers13030520] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Wang W, He H, Marín-Ramos NI, Zeng S, Swenson SD, Cho HY, Fu J, Beringer PM, Neman J, Chen L, Schönthal AH, Chen TC. Enhanced brain delivery and therapeutic activity of trastuzumab after blood-brain barrier opening by NEO100 in mouse models of brain-metastatic breast cancer. Neuro Oncol 2021:noab041. [PMID: 33659980 DOI: 10.1093/neuonc/noab041] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
12 Perrone M, Talarico G, Chiodoni C, Sangaletti S. Impact of Immune Cell Heterogeneity on HER2+ Breast Cancer Prognosis and Response to Therapy. Cancers (Basel) 2021;13:6352. [PMID: 34944971 DOI: 10.3390/cancers13246352] [Reference Citation Analysis]
13 Riller Q, Varthaman A, Sibéril S. Tight Interplay Between Therapeutic Monoclonal Antibodies and the Tumour Microenvironment in Cancer Therapy. Adv Exp Med Biol 2020;1277:127-41. [PMID: 33119870 DOI: 10.1007/978-3-030-50224-9_9] [Reference Citation Analysis]
14 Cosentino G, Plantamura I, Tagliabue E, Iorio MV, Cataldo A. Breast Cancer Drug Resistance: Overcoming the Challenge by Capitalizing on MicroRNA and Tumor Microenvironment Interplay. Cancers (Basel) 2021;13:3691. [PMID: 34359591 DOI: 10.3390/cancers13153691] [Reference Citation Analysis]
15 Chen Y, Chen D, Wang Q, Xu Y, Huang X, Haglund F, Su H. Immunological Classification of Pancreatic Carcinomas to Identify Immune Index and Provide a Strategy for Patient Stratification. Front Immunol 2021;12:719105. [PMID: 35111149 DOI: 10.3389/fimmu.2021.719105] [Reference Citation Analysis]
16 Petroni G, Buqué A, Zitvogel L, Kroemer G, Galluzzi L. Immunomodulation by targeted anticancer agents. Cancer Cell 2021;39:310-45. [PMID: 33338426 DOI: 10.1016/j.ccell.2020.11.009] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 8.5] [Reference Citation Analysis]